Clinical Dialogues™ in Pancreatic Cancer

Making Sense of Emerging Therapies in Pancreatic Cancer: Are We Finally on the Right Track?
Making Sense of Emerging Therapies in Pancreatic Cancer: Are We Finally on the Right Track?
CME, CPE
Andrew H. Ko, MD, and Tanios Bekaii-Saab, MD, FACP
Release Date: August 20, 2015
Expiration Date: August 20, 2016
The vast majority of patients with pancreatic cancer present with disease which is either metastatic or locally advanced inoperable. At that point, systemic therapy becomes the mainstay of care. Over the past several years, the standard of care has been a gemcitabine-based regimen. Most recently, two positive phase 3 trial results have led to a shift in the way patients with advanced metastatic pancreatic cancer are treated. With additional ongoing trials and the promise of additional treatment options on the horizon, it is important for community oncologists to be educated about these emerging treatments so that they can deliver optimal care to their patients.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Aduro BioTech.
View Only, CE ExpiredView Only, No Credit
 
Novel Approaches to Enhancing the Diagnosis of Pancreatic Cancer:  New Horizons and Emerging Technologies
Novel Approaches to Enhancing the Diagnosis of Pancreatic Cancer: New Horizons and Emerging Technologies
CME, CPE
Anil K. Rustgi, MD – Moderator, Koushik K. Das, MD
Release Date: December 15, 2014
Expiration Date: December 15, 2015
Leading pancreatic cancer researchers discuss new and emerging serological tests that are being investigated for pancreatic cancer and novel diagnostic approaches for cystic lesions of the pancreas.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Aduro BioTech.
View Only, CE ExpiredView Only, No Credit
 
Identification, Characterization and Recent Advances in Pancreatic Cancer
Identification, Characterization and Recent Advances in Pancreatic Cancer
CME, CPE
James J. Farrell, MD; Jill Lacy, MD; Anil Rustgi, MD
Release Date: August 27, 2014
Expiration Date: August 27, 2015
Dr. James Farrell leads a panel with pancreatic cancer experts Dr. Anil Rustgi and Dr. Jill Lacy. The discussion focuses on the identification and characterization of patients and their families who are at increased risk for pancreatic cancer and looks at the latest research being undertaken in this area. In addition, the recent advances in the treatment of metastatic pancreatic cancer and how these new advances in treatment are being used in the clinical practice setting is covered by these experts.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Aduro BioTech.
View Only, CE ExpiredView Only, No Credit
 

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2017 MediCom Worldwide, Inc. All rights reserved